We have repeatedly reported that American ginseng (AG) with a specific ginsenoside profile significantly decreases postprandial glycemia. Whether this effect is reproducible using AG with a different profile is unknown. We therefore investigated the effect of a different batch of AG on glycemia following a 75 g oral glucose tolerance test (OGTT). Methods: Using a randomized, single blind design, 12 normal subjects (six males and six females, aged 31 AE 3 y, body mass index (BMI) 28 AE 2 kg=m 2 ) received 6 g AG or placebo 40 min before a 75 g OGTT. The protocol followed the guidelines for the OGTT, with venous blood samples drawn at 7 40, 0, 15, 30, 45, 60, 90 and 120 min. Ginsenosides in the AG were assessed by established methods for HPLC-UV. Results: Repeated measures analysis of variance demonstrated that there was no significant effect of the AG on incremental plasma glucose (PG) or insulin (PI) or their areas under the curve Indices of insulin sensitivity (insulin sensitivity index (ISI)) and release (DPI 30-0 =DPG 30-0 ) calculated from the OGTT were also unaffected. The AG contained 1.66% total ginsenosides, 0.90% (20S)-protopanaxadiol (PPD) ginsenosides, and 0.75% (20S)-protopanaxatriol (PPT) ginsenosides, with the following key ratios: PPD:PPT of 1.2, Rb 1 :Rg 1 of 8.1, and Rb 2 :Rc of 0.18. Conclusions: The present batch of AG was unable to reproduce the postprandial hypoglycemic effects we observed previously. Possible explanations for this discrepancy include marked decrements in total ginsenosides and the key ratios PPD:PPT, Rb 1 :Rg 1 , and Rb 2 :Rc. These data suggest that the ginsenoside profile of AG might play a role in its hypoglycemic effects. The involvement of other components cannot, however, be precluded.
Introduction
While the use of herbal supplements has increased dramatically in recent years (Eisenber et al, 1998) , poor standardization remains a serious concern. Numerous articles (Levin et al, 1997) , editorials (Angelle Kassirer, 1998) , and commentaries (Fontanarosa & Lundberg, 1998; Hershfield, 1998; Oppel, 1998) have called for more clinical safety and efficacy testing of herbal products and the identification of active components to improve the basis for standardization. This call is of particular relevance to ginseng. The principal components used in ginseng authentication are its glycosidal saponins, called ginsenosides (Attele et al, 1999) . Interspecies variation in ginsenosides has been reported to be as high as 15-fold in dried powder and 36-fold in liquid preparations (Harkey et al, 2001) . Intraspecies variation has been shown to be of equal concern. Intrapsecies coefficient-of-variation (CV), for example, can be extrapolated from a study of American ginseng (AG) harvested at the same time from nine British Columbian farms (Li et al, 1996) . It was calculated to range from 16 to 38% for the seven most common ginsenosides and their totals and from 28 to 122% for ginsenoside-specific ratios used in its authentication. A recent advisory by the Federal Drug Administration (FDA) also recently reported that a ginseng preparation, marketed as a diabetes remedy, contained the hypoglycemic agent, sulfonylurea (Leiter, 2000) . These inconsistencies challenge the notion that the results seen with one ginseng preparation necessarily apply to others or even another batch of the same preparation. In this regard, whether other batches of AG with different ginsenoside profiles will be able to replicate the postprandial glycemic reductions we repeatedly observed with a single batch of AG is unclear (Vuksan et al, 2000a (Vuksan et al, -c, 2001a . We therefore assessed the effect of a second batch of AG from the same supplier on postprandial glycemia in the present study.
Methods

Participants
Healthy participants were recruited from faculty and students at the University of Toronto and hospital advertisements. Exclusion criteria included previously diagnosed dysglycemia, liver or kidney disease, major surgery in the last 6 months, < 18 or > 75 y of age, and morbid obesity ( > 35 kg=m 2 ). Twelve participants (six males and six females, aged 31 AE 3 y, body mass index (BMI) 28 AE 2 kg=m 2 ) were recruited who met these criteria. All gave informed written consent. The study was approved by the Research Ethics Board at St Michael's Hospital.
Treatments
Participants received either 6 g of AG or placebo in a randomized cross-over design. The AG capsules contained 3-y-old Ontario grown, dried, ground AG root (Panax quinquefolius L.) supplied by the same supplier, Chai-Na-Ta Corp., BC, Canada, that provided the original batch for which we reported (Vuksan et al, 2000a (Vuksan et al, -c, 2001a ,b) a glycemic lowering effect. This AG was the same commercially available product, but from a different batch than the original. The placebo, on the other hand, consisted of identical capsules containing corn flour. The energy, carbohydrate content and appearance of the placebo were designed to match that of the AG.
Protocol
The protocol followed the World Health Organization (WHO) guidelines for the administration of a 75 g oral glucose tolerance test (75 g OGTT; WHO Study Group, 1994) . Participants attended the Risk Factor Modification Centre at St Michaelss hospital twice following a 10 -12 h overnight fast. A minimum of 3 days separated each visit to minimize carry-over effects. Each participant was instructed to maintain the same dietary and exercise patterns the evening before each test and consume a minimum of 150 g of carbohydrate each day over the 3 days prior to the test. To ensure compliance, participants completed a questionnaire detailing pre-session information about their diet and lifestyle patterns and submitted to measurements of their body weight and total body fat, assessed by infrared-interactance using a Futrex-5000 1 (Futrex Inc., Gaithersburg, MD, USA). Upon commencement of the OGTT, participants had a catheter inserted into a forearm vein that was secured by tape and kept patent by saline. From this device a fasting 7 ml blood sample was obtained in a plasma tube. Either AG or placebo capsules were then administered with exactly 300 ml of tap water. Participants gave another blood sample after 40 min. This was followed by consumption of the 75 g oral glucose load (75 g Glucodex 1 , Technilab, Quebec, Canada) over exactly 5 min. Additional blood samples were drawn using the same technique at 15, 30, 45, 60, 90 and 120 min after the start of the challenge. Adverse symptom monitoring during each clinic visit and in the intervening washout days ( ! 3 days) was assessed by subjective seven-point bipolar visual analogue scales.
Ginseng analyses
Ginsenoside profiles of the AG and placebo used on the present study were measured using standard techniques. The ginsenosides comprise principally a family of steroids called dammarane-type triterpene glycosides with either (20S)-protopanaxadiol (PPD) or (20S)-protopanaxatriol (PPT) as the aglycone. The four main PPD ginsenosides (Rb 1 , Rb 2 , Rc, Rd) and three main PPT ginsenosides (Rg 1 , Re, Rf) were analyzed using a following HPLC-UV techniques developed for the American Botanical Council (ABC) Ginseng Evaluation Program (Fitzloft et al, 1998) . The HPLC conditions included: chromatograph, Beckman HPLC system; column, a reverse-phase Beckman ultrasphere C-18, 5 mm octadecylsilane, 250Â4.6 mm column; mobile phase, de-ionized water and acetonitrile; flow rate, 1.3 ml=min; UV detection, a module 168 diode-array detector set at 203 nm. The ginsenoside standards for Rg 1 and Re were provided by Dr H Fong University of Illinois and the Rf, Rb 1 , Rc, Rb 2 , Rd standards were provided by Indofine Chemical Co., Somerville, NJ, USA.
Blood glucose analysis All samples were separated by centrifuge and the plasma immediately frozen at 720 C pending analysis. Analyses of glucose concentration of each sample were done by the glucose oxidase method (Kadish & Hall, 1965 ) and the 
Statistical analyses
Incremental plasma glucose (PG) and insulin (PI) curves were plotted and the positive incremental area under the curve (AUC) was calculated (Wolever et al, 1991) . The whole body insulin sensitivity index (ISI; Matsuda & De Fronzo, 1999) and the early insulin secretion index, DPI 30-0 =DPG 30-0 (Phillips et al, 1995) , were also calculated from derived OGTT equations. ISI was calculated using fasting PG (FPG) and PI (FPI) with mean OGTT outcome, according to the formula (Matsuda & De Fronzo, 1999) : 10 000 divided by the square root of ((FPGÂFPI)Â(mean-PGÂmean-PI)), where PG is expressed in mg=dl (0.0551 mmol=l) and PI in mU=ml (6 pmol=l). The early insulin secretion index, DPI 30-0 =DPG 30-0 , was calculated as the change in PI from 0min to 30 min divided by the change in PG over the same period (Phillips et al, 1995) . Statistical analyses were then performed using the Number Cruncher Statistical System (NCSS) 2000 software (NCSS statistical software, Kaysville, UT, USA). Repeated measures two-way ANOVA assessed the interactive and independent effects of treatment and time on incremental PG and PI. One-way repeated measures ANOVA assessed differences in incremental PG and PI at each time point between AG and placebo. This statistic also assessed differences in PG AUC, PI AUC, ISI and DPI 30-0 =DPG 30-0 . Paired Student t-tests assessed differences in subjective ratings of symptoms for both the clinical testing and washout periods. All results were expressed as mean AE s.e.m. and significant at P < 0.05.
Results
All participants followed the study protocol safely and without difficulty. A minimum of 150 g of carbohydrate was consumed over the 3 days prior to each test. Baseline anthropometry and fasting plasma glucose and insulin were maintained. The participants consumed the placebo and AG capsules in the self-standardized amount of time and the 75 g Glucodex 1 oral glucose load in the allotted 5 min for each test. There were also no differences in reported symptoms of bloating, belching, nausea, dizziness, headache, diarrhea, flatulence polyuria, insomnia, anxiety, numbness, light-headedness, thirst or cramping between placebo and AG treatment during the clinic visits or the intervening washout period. Figure 1 shows the effect of the present batch of AG and our original batch of AG (Vuksan et al, 2001b) on postprandial PG and PI responses. Panel (A) compares the effect of 6 g of the present AG batch with placebo on incremental PG and PI following a 75 g OGTT. Two-way repeated measures ANOVA demonstrated that there was a significant effect of time (P < 0.0001) but no effect of treatment (P ¼ 0.56, P ¼ 0.69) on PG and PI, with no interaction for either parameter (P ¼ 0.42, P ¼ 0.18). This was reflected in a lack of effect of AG on PG-AUC (P ¼ 0.96) and PI-AUC (P ¼ 0.58). It was also reflected in the lack of effect on derived indices of whole body insulin sensitivity (ISI; P ¼ 0.76) and first release insulin secretion (DPI 30-0/ =DPG 30-0 ; P ¼ 0.79). Panel (B) compares the effect of 6 g of our original AG batch on incremental PG and PI following a 75 g OGTT with a historical control (a 75 g OGTT done alone previously). Two-way repeated measures ANOVA demonstrated a significant effect of time (P < 0.0001) on PG and PI, with significant independent (P ¼ 0.016) and interactive effects (P ¼ 0.046) of treatment on PG only. Pairwise comparisons showed that 45 min, 60 min, 90 min and AUC PG were significantly decreased (P < 0.05). This was reflected in a significant effect of AG on PG-AUC (P ¼ 0.02). Neither PI-AUC (P ¼ 0.51) nor whole body insulin sensitivity (ISI; P ¼ 0.49) nor first release insulin secretion DPI 30-0 =DPG 30-0 P ¼ 0.67) were affected (Vuksan et al, 2001b) . Table 1 shows the ginsenoside analysis for the placebo capsules, the present batch of AG, and our original batch (Vuksan et al, 2000a (Vuksan et al, -c, 2001a . The composition of both the present and our original batch is consistent with panax quinquefolius L. Key ratios and the presence and absence of various ginsenosides are used in the authentication of ginseng. A ratio of Rb 1 :Rg 1 > 3 (Ma et al, 1996; Awang et al, 2000) and ratios of Rg 1 :Re and Rb 2 :Rc < 1 have been shown to be indicative of Panax quinquefolius L. (Chan et al, 2000; Wang et al, 1999) . The most powerful marker is the absence of Rf, a ginsenoside not found in AG and distinctive for Asian ginseng (Ma et al, 1996; Awang et al, 2000; Chan et al, 2000; Li et al, 2000) . These criteria were met by both batches of AG. However, within these criteria, there were still large differences between the two batches. The present batch of AG had 48% less total ginsenosides, 51% lower PPD:PPT ratio, at the expense of PPD, 47% lower Rb 1 :Rg 1 ratio, at the expense of Rb 1 , and 28% lower Rb 2 :Rc ratio, at the expense of Rb 2 .
Discussion
The present study demonstrates a favorable side-effect profile of the present AG batch but with a lack of effect on postprandial indices of glycemia and insulinemia. Although insufficient quantities of the original AG batch precluded a bioequivalence study, existing data from earlier studies provided a basis for indirect comparisons. The lack of efficacy observed with the present AG batch is in direct contrast to this existing data. We noticed previously that 6 g of our original AG batch lowered the plasma glucose response to a 75 g OGTT significantly (P < 0.05) in eight nondiabetic subjects (Vuksan et al, 1991b) . These findings are in addition to the reductions we reported with the original AG batch at doses from 1 to 9 g, following a capillary blood glucose protocol using a 25 g OGTT in people with (Vuksan et al, 2000a,b) and without (Vuksan et al, 2000c (Vuksan et al, , 2001a diabetes.
Reasons for this disagreement in findings are not clear. The most compelling explanation is compositional differVariable effects of American ginseng JL Sievenpiper et al ences. Although the ginsenoside profile confirmed that the present AG batch was also Panax quinquefolius L, there were marked decrements in ginsenosides compared with our original batch. It is possible that specific active ginsenosides were below the efficacy range or, in the case of the ratios, favored counter-regulatory effects of ginsenosides present in higher relative proportions.
There is some evidence to support a role of ginsenoside differences in variable glycemic effects. The efficacy range for various ginsenosides can be high. The 3 main PPD ginsenosides measured on the present study, Rb 1 , Rb 2 , Rc, have been shown only to be able to increase glucose transport at higher levels ( > 1.0 mM) in sheep erythrocytes (Hasegawa et al, 1994) . It was also with a high dose of Rb 2 (10 mg=kg) that an increase in glycolytic enzymes and a decrease in gluconeogenic enzymes were observed in rat liver (Yokozawa et al, 1984 (Yokozawa et al, , 1985 . The 10 mg=kg dose used in these latter studies is $ 100-fold higher than the 0.077 mg=kg equivalent for a 70 kg person that we fed in the present study. This suggests that these ginsensoides might have been present in insufficient quantities in the present batch of AG to have similar hypoglycemic related effects. The limitation of this argument is that although the relative proportion of ginsenosides was less in the present batch of AG, the dose administered was double or greater than that found to be efficacious with our original batch of AG (Vuksan et al, 2000a (Vuksan et al, -c, 2001a ). The implication is that for even those ginsenosides which were $ 50% lower, the quantity administered would be roughly equivalent.
If the present AG was not administered at a quantity below the efficacy range of its active ginsenosides, then counter-regulatory effects of specific ginsenosides must be considered. A water extract of Asian ginseng, expected to have lower PPD:PPT ratios (Cui, 1995) , inhibited noninsulin stimulated 2-deoxy-D-[2-3 H]glucose (2-DG) uptake in 3T3-L1 adipocytes at the highest dose of 10 000 mg=ml and The postprandial glycemic and insulinemic effects for our original AG batch used in five previous studies (Vuksan et al, 2000a (Vuksan et al, -c, 2001a ). The line plots and bars represent the incremental change and AUC for plasma glucose and insulin following a 75 g OGTT done alone previously (n) or with 6 g AG taken 40 min before the test (d) in eight healthy, nondiabetic subjects. P-values are for repeated measures one-way ANOVA adjusted with the Tukey -Kramer procedure. Data are mean AE s.e.m.
Variable effects of American ginseng
JL Sievenpiper et al significantly inhibited insulin stimulated 2-DG uptake compared with control in a dose-related manner (Hong et al, 2000) . These data suggest a possible inhibition of GLUT-1 at high doses and the insulin-dependent GLUT-4 with increasing doses. PPTs were also observed to inhibit [
14 C]-a-mean glucose uptake in a dose dependent manner at doses from 10 to 100 mg in cultured rabbit renal proximal tubular cells in which the sodium coupled glucose transporter, SGLT-1, mediates glucose uptake (Han et al, 1999) . As the relative proportion of PPT was increased in the PPD:PPT ratio in the present AG batch studied, this might have had an opposing effect on glucose transport mechanisms. Taken together, the AG ginsenoside profile should be considered as a possible mediator of its effects.
Other components alone or together with ginsenosides might also have influenced the results. For example, the peptidoglycans (panaxans from Asian ginseng and quinquefolans from AG) and polysaccharides (ginsenans) from ginseng have shown pharmacological activity. Of these only the former have shown glycemic effects. Panaxans A-L (Konno et al, 1984 Oshima et al, 1985 Oshima et al, , 1987 and quinquefolans A-C have shown hypoglycemic effects with varying potencies when administered as intraperintoneal injections in both normal and alloxan induced hyperglycemic mice. However, their influence is dubious. Whether the main route of commercial administration, oral administration, will result in the same effects in humans is uncertain. Digestive gut and colonic microfloral enzymes would likely degrade these components and those that escaped digestion would be impermeable across the enterocytes. Both inevitabilities would preclude any activity. There is, nevertheless, data that suggest that functional amounts of some intact peptides and peptidoglycans can be absorbed (Yamamoto, 2001 ). In the absence of measurements of these components in our ginseng batches, this still leaves open the possibility of their interaction in effects.
In conclusion, different batches of AG from the same supplier can give differential results. Although ginsenoside differences are probably driving effects, other components such as quinquefolans and ginsenans might share some responsibility. This situation warns against the lack of ginseng standardization. It also warns against standardization that is without basis. That is, the standardization of total ginsenosides or specific ginsenosides seen in some extracts and preparations (Cui, 1995) is of little benefit if the efficacy of the standards is unknown. Together these concerns highlight the need for greater research to understand the role of ginsenosides, quinquefolans, ginsenans, and other isolated components and the effect their variability has on safety and efficacy. In this regard, more detailed animal and in vitro work to determine the hypoglycemic activities if AG and its components is required, with the ultimate goal of identifying candidate components for clinical safety and efficacy testing. Such efforts will increase the ability of researchers to perform interpretable, generalizable studies, the consumer to select consistently efficacious and safe products, and health practitioners to assess possible therapeutic benefits and adverse ginseng -drug interactions. Until then, advocacy of AG for any of its indications is premature. Determined by HPLC-UV analyses (Fitzloff et al, 1998) . The present AG batch represents the AG batch tested in the present study and the original AG batch represents the AG batch shown to be efficacious in our previous studies (Vuksan et al, 2000a (Vuksan et al, -c, 2001a .
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